1
|
Clark AL, Bruce Wirta S, Zhou M, Kazmi S, Goode KM, Pellicori P, Corda S, Balas B, Calado F, Cleland JGF. P6530What proportion of patients with heart failure are candidates for sacubitril/valsartan? Differences between guideline recommendations and regulatory labels. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A L Clark
- Hull York Medical School (at University of Hull), Castle Hill Hospital, Department of Cardiology, Kingston upon Hull, United Kingdom
| | - S Bruce Wirta
- Novartis Sweden AB, Real World Evidence Center of Excellence, Stockholm, Sweden
| | - M Zhou
- IQVIA, Real-World Insights, Basel, Switzerland
| | - S Kazmi
- Hull York Medical School (at University of Hull), Castle Hill Hospital, Department of Cardiology, Kingston upon Hull, United Kingdom
| | - K M Goode
- Hull York Medical School (at University of Hull), Castle Hill Hospital, Department of Cardiology, Kingston upon Hull, United Kingdom
| | - P Pellicori
- Hull York Medical School (at University of Hull), Castle Hill Hospital, Department of Cardiology, Kingston upon Hull, United Kingdom
| | - S Corda
- Novartis, Basel, Switzerland
| | - B Balas
- Novartis, Basel, Switzerland
| | | | - J G F Cleland
- University of Hull, Kingston upon Hull, United Kingdom
| |
Collapse
|